Shots: Takeda initiates the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), TAK-888 for the treatment of high-risk individuals with COVID-19 and evaluates its marketed and pipeline products as viable candidates for COVID-19 Takeda is currently working with multiple national health and regulatory agencies in the US, EU, and Asia to expedite the research of […]Read More
